{"entity":{"id":"element-biosciences","kind":"company","name":"Element Biosciences","aka":[],"tldr":"AVITI benchtop sequencer with avidity chemistry, competing on accuracy and cost with mid-throughput Illumina systems.","summary":"Element Biosciences, based in San Diego, makes the AVITI benchtop sequencer, which uses avidity chemistry to compete on accuracy and cost with mid-throughput Illumina systems. AVITI and AVITI24, which runs multiomics on a single instrument, were launched between 2022 and 2024. OnCo links it to new short-read sequencing platforms. Whether a benchtop challenger can win clinical laboratories away from the incumbent when assays are validated on Illumina is the open question. The short-read platforms page carries the wider picture.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.elementbiosciences.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["next-gen-short-read-platforms"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://www.elementbiosciences.com","investors":[],"funding":[]},"route":"/companies/element-biosciences/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/"}]}}